Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Overview of attention for article published in Annals of Oncology, October 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 4 episodes from 4 podcasts.

Dr. Jasmine Sukumar and Dr. Dionisia Quiroga discuss advances in adjuvant therapy for patients with early breast cancer and…

1. BRCA 1/2 genes and relation to malignancy2. Family history taking and identifying patients for genetic testing3. Risk…

No último episódio desse ano, temos um programa diferente: um resumo, com discussões das importantes novidades que tivemos ao…

A primeira análise interina pré-especificada (IA) do estudo de Fase 3 OlympiA demonstrou melhora estatisticamente significativa…

This page shows the most recent posts that mention this research output. Click here to find out how to access more activity.